Want to see AU:NTI full AI Analyst Report?
Top Page
Neurotech International
(Sydney:NTI)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.02
â–²(90.00% Upside)
Action:Reiterated
Date:10/14/26
The score is held down primarily by weak financial performance (zero revenue in 2026, persistent losses, and ongoing cash burn alongside a shrinking equity/asset base). Technicals provide some offset with price strength above major moving averages and a positive MACD, but the elevated RSI signals a stretched setup. Valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
The absence of total debt reduces leverage pressure and avoids interest obligations, giving Neurotech greater financial flexibility than a similarly loss-making company with borrowings. This can help preserve resources for research, clinical development, and regulatory work while limiting refinancing risk.
Negative Factors
No current revenue
The return to zero revenue demonstrates that the business has not yet established dependable commercial sales. Without recurring top-line support, funding for research and commercialization remains dependent on available cash and external financing, making future operating progress financially fragile.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of total debt reduces leverage pressure and avoids interest obligations, giving Neurotech greater financial flexibility than a similarly loss-making company with borrowings. This can help preserve resources for research, clinical development, and regulatory work while limiting refinancing risk.
Read all positive factors
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.09M
Dividend YieldN/A
Average Volume (3M)6.37M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth-100.00%
EPS Growth50.49%
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,616,070,000
10 Day Avg. Volume3,452,550
30 Day Avg. Volume6,368,072
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)27.08
Price to Sales (P/S)0.00
P/FCF Ratio-3.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$3.00M
Neurotech International Business Overview & Revenue Model
Company Description
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and com...
Neurotech International Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.44M | 1.96K | 5.96K | 38.26K |
| Gross Profit | 0.00 | 2.44M | -5.87K | 4.21K | -535.21K |
| EBITDA | -11.33M | -10.74M | -8.24M | -8.98M | -3.36M |
| Net Income | -6.54M | -10.60M | -5.07M | -7.79M | -3.36M |
Balance Sheet | |||||
| Total Assets | 2.75M | 3.24M | 12.21M | 5.31M | 2.02M |
| Cash, Cash Equivalents and Short-Term Investments | 2.39M | 3.03M | 11.63M | 5.03M | 1.90M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.14M | 285.74K | 314.70K | 1.35M | 592.98K |
| Stockholders Equity | 611.14K | 2.95M | 11.90M | 3.96M | 1.43M |
Cash Flow | |||||
| Free Cash Flow | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Operating Cash Flow | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -3.21K |
| Financing Cash Flow | 3.58M | 429.53K | 11.19M | 9.45M | 26.40K |
Neurotech International Technical Analysis
Positive
0.01
Price Trends
0.01
Positive
0.01
Positive
0.01
Positive
Market Momentum
<0.01
Negative
71.10
Negative
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NTI, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 71.10 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NTI.
Neurotech International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$9.16B | 63.75 | 8.01% | 2.46% | -0.90% | -62.14% | |
57 Neutral | AU$45.95M | 209.09 | 0.93% | ― | 18.54% | ― | |
55 Neutral | AU$65.93M | -24.79 | -5.44% | ― | 2.73% | 25.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$139.43M | -16.54 | -46.84% | ― | ― | 20.40% | |
47 Neutral | AU$29.09M | -4.09 | -201.54% | ― | -100.00% | 50.49% | |
42 Neutral | AU$26.66M | -2.53 | -103.48% | ― | -22.43% | 15.02% |
* Healthcare Sector Average
AU:NTI
Neurotech International
0.02
<0.01
6.25%
AU:COH
Cochlear
142.20
-136.91
-49.05%
AU:CMP
Compumedics Limited
0.24
-0.11
-31.88%
AU:SOM
Somnomed Limited
0.30
-0.56
-65.12%
AU:EMV
EMvision Medical Devices Ltd.
1.50
-0.27
-15.25%
AU:CBL
Control Bionics Ltd.
0.05
0.02
44.12%
Neurotech International Corporate Events
Neurotech advances autism drug NTI164 with Phase 3 trial, FDA IND and new funding
Oct 27, 2026
Neurotech International has advanced its autism drug candidate NTI164 into pivotal Phase 3 development, dosing the first patient in its national Beyond Harmony trial in Australia and initiating six hospital sites to enrol up to 200 paediatric ASD ...
Neurotech Flags High Risks as It Pursues Neurodevelopmental Disorder Therapies
Oct 19, 2026
Neurotech International has outlined its strategic focus on developing treatments for neurodevelopmental disorders, emphasizing the inherent risks and uncertainties in drug research and commercialisation. The company highlights that only a small f...
Neurotech Director Andrew Chapman Boosts Equity Stake
Oct 7, 2026
Neurotech International has disclosed a change in director Andrew Chapman’s relevant interests, detailing adjustments in both direct and indirect holdings of fully paid ordinary shares. The notice shows Chapman and related entities acquired ...
Neurotech International Releases 2026 Annual Report
Oct 5, 2026
Neurotech International has released its 2026 Annual Report, detailing the company’s governance, financial performance, and audited statements for the year. The report outlines board composition, confirms independent auditing and share regis...
Neurotech International Sets November AGM, Moves to Digital Meeting Materials
Oct 1, 2026
Neurotech International has called its Annual General Meeting for 5 November 2026 at BDO Australia’s Melbourne offices, with shareholder voting eligibility set for those on the register at 4:00 p.m. AEDT on 3 November 2026. The company is sh...
Neurotech Starts Pivotal Phase 3 Trial of NTI164 for Autism
Sep 20, 2026
Neurotech International has begun dosing the first patient in its pivotal Phase 3 Beyond Harmony trial of NTI164 for children with Autism Spectrum Disorder, moving the cannabinoid-based therapy into late-stage development. The national, multicentr...
Neurotech International Adds Major Shareholder Andrew Chapman to Board
Sep 8, 2026
Neurotech International has appointed Andrew Chapman as a director effective 8 September 2026, signalling a strengthening of its board with an individual closely linked to multiple investment entities. The appointment is accompanied by an update o...
Neurotech International Options Lapse Simplifies Capital Structure
Sep 8, 2026
Neurotech International Limited has confirmed the lapse of 5,000,000 options exercisable at $0.16 and 10,000,000 options exercisable at $0.18, both expiring in February 2030. These options have ceased because the conditions attached to the rights ...
Neurotech reshapes board as it advances paediatric cannabinoid trials
Sep 8, 2026
Neurotech International has announced several board and management changes, appointing Merchant Funds Management founder Andrew Chapman as a non-executive director, bringing more than 25 years of capital markets and biotechnology financing experie...
Neurotech Discloses Final Director Interest as Anthony Filippis Steps Down
Sep 8, 2026
Neurotech International Limited has announced that director Anthony Filippis ceased to be a director on 7 September 2026, triggering a final disclosure of his relevant interests in the company’s securities. While he holds no shares directly,...
Neurotech Narrows Loss as R&D Grants Drive Revenue Surge
Aug 26, 2026
Neurotech International reported an 86% rise in revenues to $4.8 million for the year ended 30 June 2026, driven almost entirely by a substantial increase in RD grant income. Despite this uplift, the company remains loss-making, but narrowed its l...
Neurotech Elevates Mark Davies to Executive Chairman as Phase III Cannabinoid Program Advances
Aug 17, 2026
Neurotech International, a clinical-stage biopharmaceutical developer of cannabinoid-based therapies for paediatric neurological disorders, is advancing its lead oral drug candidate NTI164 through late-stage clinical development. The company’...
Neurotech Confirms Compliance as New Shares Enter Secondary Trading
Aug 11, 2026
Neurotech International Ltd is a clinical-stage biopharmaceutical company developing NTI164, an oral cannabinoid therapy for paediatric neurological and neuropsychiatric disorders, including Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome....
Neurotech International Seeks ASX Quotation for 293 Million New Shares
Aug 11, 2026
Neurotech International Limited has applied for quotation on the ASX of 293,328,277 ordinary fully paid shares, with an issue date of 11 August 2026. The new securities form part of previously announced transactions, signalling a substantial expan...
Neurotech raises $4.5m to fund pivotal ASD Phase III trial
Aug 3, 2026
Neurotech International has secured binding commitments for a $4.5 million share placement, bringing in existing and new institutional and sophisticated investors at an issue price of $0.014 per share. The capital raising strengthens the company&#...
Neurotech secures FDA IND nod and U.S. patent wins as autism drug program advances
Jul 31, 2026
Neurotech International’s June-quarter activities centred on advancing NTI164, with operational emphasis on the Phase 3 Beyond Harmony trial in paediatric autism and preparations for regulatory submissions in multiple markets. The company is...
Neurotech Autism Trial Data Secures Publication in Leading Neurotherapeutics Journal
Jul 29, 2026
Neurotech International has reported that data from its Phase II/III Harmony Study of NTI164 in children with autism spectrum disorder have been accepted for publication in Neurotherapeutics, a leading peer‑reviewed journal of the American S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.